Chemotherapy News and Research

Latest Chemotherapy News and Research

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

Light therapy can help preserve vocal cord function for patients with early stage laryngeal cancer: Study

Light, or photodynamic, therapy can help preserve the voice and vocal cord function for patients with early stage laryngeal (voice box) cancer, according to a study from Henry Ford Hospital in Detroit.

29 Jan 2011

New surgical approach can remove throat tumor and rebuild trachea

Using a novel surgical approach, it's possible to rebuild the trachea and preserve a patient's voice after removing an invasive throat tumor, according to a new report from Henry Ford Hospital in Detroit.

29 Jan 2011

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.

28 Jan 2011

Survey finds public lack knowledge of radiotherapy

Fewer than one in ten people think radiotherapy is a modern cancer treatment according to the results of a survey published Friday.

28 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Study suggests newborn diagnosis can improve survival in SCID patients

Severe Combined Immunodeficiency occurs in just one out of every 50,000 to 100,000 births in the United States, yet it is the most serious primary immunodeficiency disorder. A study published today in Blood, the Journal of the American Society of Hematology, demonstrates that babies with SCID who are diagnosed at birth and receive a hematopoietic stem cell transplant, which is the transplantation of blood-forming stem cells, have significantly improved survival.

28 Jan 2011

XYTOS shares cancer patient treatment results

XYTOS Shares Patient Results.

28 Jan 2011

Magnetic nanoparticles for ovarian cancer treatment

A paper published in the January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option - one that would use an outside-the-body filtration device to remove a large portion of the free-floating cancer cells that often create secondary tumors.

28 Jan 2011

Gene signature can accurately predict breast cancer outcomes

Researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre, the Research Institute of the McGill University Health Centre, the Dana-Farber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

28 Jan 2011

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Sanofi-aventis and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival

28 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

Healthcare at Home acquires Sciensus

Healthcare at Home Ltd, Europe's leading international provider of home-based healthcare and specialty pharmacy services, is today pleased to announce that it has acquired Sciensus Ltd, a provider of health informatics for clients across the NHS and the pharmaceutical industry.

27 Jan 2011

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer.

27 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial

Cutting edge, patient-specific vaccine treatments like DCVax® provide for a longer life expectancy along with a better quality of life for brain cancer patients, an improvement over current conventional brain tumor treatments. "The vaccine that I received has extended the median survival of Grade IV brain cancer (GBM) from 14.6 months, with conventional treatment, to over 36 months," stated Bob Gibbs, a 7 year brain cancer survivor, who has defied the odds statistically, thanks to the experimental brain cancer vaccine DCVax®.

25 Jan 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Extreme morning sickness drug comes at a price

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Light therapy can help preserve vocal cord function for patients with early stage laryngeal cancer: Study

New surgical approach can remove throat tumor and rebuild trachea

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Survey finds public lack knowledge of radiotherapy

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Study suggests newborn diagnosis can improve survival in SCID patients

XYTOS shares cancer patient treatment results

Magnetic nanoparticles for ovarian cancer treatment

Gene signature can accurately predict breast cancer outcomes

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

Healthcare at Home acquires Sciensus

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in